We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VLTO:NYSEVeralto Corp Analysis

Data as of 2026-09-07 - not real-time

$96.31

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

The moving-average structure behind Veralto Corporation is bullish at $96.31, with short-term averages leading the long-term ones. It has gained 4.7% over the past 30 days. Momentum indicators put RSI at 47.3 (neutral) with MACD reading bearish. Price has been bracketed by support at $95.63 and resistance at $101.00.
Multiples put this in fair territory: 24.3 times earnings against the sector's 28.5. Sell-side targets cluster 18.4% above the current quote. Revenue is growing at 7.5% on a 17.3% profit margin. The 0.54% dividend yield looks covered by current payout levels.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 26.0%, a beta of 0.27 and a maximum drawdown of 24.6%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons line up on buy — conviction 5 out of 10.

Top Market Events

Veralto Corp VLTO reports a robust 7.6% sales increase and raises full-year EPS guidance, despite facing market...Weitz Investment Management, an investment management firm, released its second-quarter Q2 2026 investor letter for the...Seeking Alpha1monVeralto Corporation VLTO Q2 2026 Earnings Call TranscriptHello.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 93.43
  • MACD momentum is negative

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 24.3 versus sector average of 28.5
  • Trading above the 200-day average of 93.43

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • P/E of 24.3 versus sector average of 28.5
  • Analyst targets imply +18.4% versus the current price
  • Profit margin of 17.3% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth7.50%
Profit Margin17.35%
P/E Ratio24.3
ROE34.31%
ROA10.31%
Debt/Equity115.98
P/B Ratio7.6
Op. Cash Flow$1.1B
Free Cash Flow$807.1M
Industry P/E28.5

Technical Analysis

TrendBullish
RSI47.3
Support$95.63
Resistance$101.00
MA 20$97.94
MA 50$95.15
MA 200$93.43
MACDBearish
VolumeIncreasing
Fear & Greed Index95.48

Valuation

Fair Value$51.56
Target Price$114.00
Upside/Downside18.37%
GradeFair
TypeGrowth
Dividend Yield0.54%

Risk Assessment

Beta0.27
Volatility26.05%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.